Home » Newsletters » BioWorld Science

BioWorld Science

April 10, 2014

View Archived Issues

Phase II interim results show improvements in infantile hypophosphatasia with asfotase alfa

GlaxoSmithKline patents novel RIP-2 inhibitors

Sideromics completes pre-IND meeting with FDA for siderocillin

First-in-human results presented for CO-1686 in EGFR-mutant NSCLC

Phase IIb results presented for bococizumab for the treatment of hypercholesterolemia

Roche discloses novel TaR-1 ligands

Bristol-Myers Squibb patents new endothelial lipase inhibitors

ERYTECH adds new product candidate to development pipeline

Kainos Medicine discloses new adenosine A3 receptor agonists

Companies simultaneously file NDAs for vemurafenib and companion diagnostic in Japan

French team presents novel V2 receptor antagonist peptides

Spero Therapeutics to develop approach for drug-resistant bacterial infections

Myriad Genetics submits premarket approval application to FDA for BRACAnalysis

Cancer Research Technologies and Teva collaboration yields novel aPKC inhibition

BLU-9931 shows antitumor activity in vitro and in in vivo HCC models with aberrant FGF-19

Hetlioz available in U.S. for non-24-hour sleep-wake disorder

Oricula Therapeutics secures intellectual property and funding to prevent hearing loss

FDA places clinical hold on Halozyme's phase II trial of PEGPH-20 for pancreatic cancer

GE Healthcare Japan enters collaboration with Nihon Medi-Physics for Abeta-imaging product

Aegerion Pharmaceuticals begins phase III trial of lomitapide in Japan

VenatoRx receives NIH grant for biodefense work

PeptiDream develops anti-influenza macrocyclic peptide therapeutic

Alkermes reports topline results from a pivotal phase III study of aripiprazole lauroxil

Pfizer describes activity of oncolytic Trop-2 antibody-drug conjugate

Pharmacyclics files supplemental NDA in U.S. for Imbruvica

Domainex compounds show activity in models of inflammation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...